Clinically localised prostate cancer is microsatellite stable.
BJU Int
Service d'Urologie, CHU d'Angers, Centre de Recherche pour les Pathologies Protatiques, Université Paris VII, Paris, France, and Department of Pathology, Royal Hallamshire Hospital, Sheffield, UK.
Published: May 2007
Objectives: To determine the frequency of microsatellite instability (MSI) change with mono-, di- and tetranucleotide markers in clinically localized prostate cancer, and to correlate those markers with clinical and pathological variables.
Materials And Methods: Two forms of MSI have been described in human cancer: MSI typical of hereditary nonpolyposis colon cancer, defined with mono- and dinucleotide repeat MS; and a second variety of MSI is best seen at selective tetranucleotide repeats, i.e. elevated microsatellite alterations at select tetranucleotides (EMAST). Prostate specimens were taken from 50 patients. The MS analysis used the Bethesda consensus panel (BCP) and four tetranucleotide loci shown to detect the presence of EMAST.
Results: All but four tumours were stable for the 14 loci investigated. There were two (4%) cases with adenomatous polyposis coli (APC) instability among the BCP markers and the same instability rate (4%) amongst the EMAST markers. These four tumours were all unstable at one locus of the 10 markers of the BCP that classified them as MS stable.
Conclusions: The MSI related to a mismatch repair deficiency or to the EMAST does not seem to be important in prostate cancer in the early stages of the disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1464-410X.2006.06723.x | DOI Listing |
Similar Publications
Predicting pathological tumor volume in prostate cancer lesions: A head-to-head comparison of micro-ultrasound vs. MRI.
Urol Oncol
March 2025
Department of Urology, Lausanne University Hospital, Lausanne, Switzerland. Electronic address:
Background And Objective: Our objective was to evaluate the agreement between micro-ultrasound, MRI and pathological tumor and prostate volume.
Methods: Retrospective analysis of consecutive prostate cancer patients with MRI and micro-ultrasound diagnostic assessment who subsequently underwent radical prostatectomy. Tumor and prostate volume on micro-ultrasound and MRI imaging calculated by a dedicated software were compared to those of the prostatectomy specimen.
Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage.
Expert Opin Drug Metab Toxicol
March 2025
Department of Pharmacy, Hospital Del Mar, Barcelona, Spain.
Introduction: New androgen receptor pathway inhibitors (ARPIs) are an essential part of the treatment strategy for patients with metastatic hormone-sensitive prostate cancer (mHSPC). Despite the good tolerability of ARPIs, after treatment is started, drug-drug interactions (DDIs) between these and other medications frequently taken by these patients may appear. DDIs may reduce the therapeutic effect of both and lead to increased adverse events.
View Article and Find Full Text PDFDeciphering the mechanisms of PARP inhibitor resistance in prostate cancer: Implications for precision medicine.
Biomed Pharmacother
March 2025
Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, PR China; Department of Urology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong Province, PR China. Electronic address:
Prostate cancer is a leading malignancy among men. While early-stage prostate cancer can be effectively managed, metastatic prostate cancer remains incurable, with a median survival of 3-5 years. The primary treatment for advanced prostate cancer is androgen deprivation therapy (ADT), but resistance to ADT often leads to castrationresistant prostate cancer (CRPC), presenting a significant therapeutic challenge.
View Article and Find Full Text PDFAnalyzing Online Search Trends for Kidney, Prostate, and Bladder Cancers in China: Infodemiology Study Using Baidu Search Data (2011-2023).
JMIR Cancer
March 2025
Urology Department, The Second Affiliated Hospital of Nanchang University, Nanchang University, Nanchang, China.
Background: Cancers of the bladder, kidney, and prostate are the 3 major genitourinary cancers that significantly contribute to the global burden of disease (GBD) and continue to show increasing rates of morbidity and mortality worldwide. In mainland China, understanding the cancer burden on patients and their families is crucial; however, public awareness and concerns about these cancers, particularly from the patient's perspective, remain predominantly focused on financial costs. A more comprehensive exploration of their needs and concerns has yet to be fully addressed.
View Article and Find Full Text PDFDynamic contrast-enhanced ultrasound (DCEUS) is an imaging modality for assessing microvascular perfusion and dispersion kinetics. However, the presence of speckle noise may hamper the quantitative analysis of the contrast kinetics. Common speckle denoising techniques based on low-rank approximations typically model the speckle noise as white Gaussian noise (WGN) after the log transformation and apply matrix-based algorithms.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.